Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -11.06% is in line with its 5-year average of -12.26%, around the middle of its 5-year range (-22.62%–-2.96%).
As of the fiscal period ended Tuesday, June 30, 2026. 1.62% above its 12-month average of -11.24%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): -11.06%.
RETURN ON EQUITY (ROE)
-11.06%
RETURN ON EQUITY (ROE) AVG TTM
-11.24%
RETURN ON EQUITY (ROE) AVG 3Y
-10.18%
RETURN ON EQUITY (ROE) AVG 5Y
-12.26%
RETURN ON EQUITY (ROE) AVG 10Y
N/A
RETURN ON EQUITY (ROE) AVG 15Y
N/A
RETURN ON EQUITY (ROE) AVG 20Y
N/A
CURRENT VS TTM AVG
+1.62%
CURRENT VS 3Y AVG
-8.64%
CURRENT VS 5Y AVG
+9.85%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-39.55%
median of 548 covered companies
CURRENT VS SECTOR MEDIAN
+72.04%
vs the sector median at left
Janux Therapeutics, Inc.
Market Cap
$998.42M
Return on Equity (ROE)
-11.06%
TTM Avg
-11.24%
3Y Avg
-10.18%
5Y Avg
-12.26%
Market Cap
$997.34M
Return on Equity (ROE)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.01B
Return on Equity (ROE)
-52.47%
TTM Avg
-18.98%
3Y Avg
-16.96%
5Y Avg
-116.25%
Market Cap
$990.12M
Return on Equity (ROE)
-15.09%
TTM Avg
46.85%
3Y Avg
62.20%
5Y Avg
62.20%
Market Cap
$985.37M
Return on Equity (ROE)
36.64%
TTM Avg
876.73%
3Y Avg
395.64%
5Y Avg
252.56%
Market Cap
$982.03M
Return on Equity (ROE)
-25.78%
TTM Avg
29.18%
3Y Avg
31.59%
5Y Avg
31.59%
Market Cap
$1.02B
Return on Equity (ROE)
-0.69%
TTM Avg
-24.98%
3Y Avg
-8.92%
5Y Avg
-2.80%
Market Cap
$1.02B
Return on Equity (ROE)
-63.62%
TTM Avg
-41.08%
3Y Avg
-23.78%
5Y Avg
-22.76%
Market Cap
$1.02B
Return on Equity (ROE)
-4.51%
TTM Avg
-33.13%
3Y Avg
-42.62%
5Y Avg
-42.62%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Janux Therapeutics, Inc. (JANX) | $998.42M | -11.06% | -11.24% | -10.18% | -12.26% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $997.34M | N/A | N/A | N/A | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | -52.47% | -18.98% | -16.96% | -116.25% |
| Aktis Oncology, Inc. (AKTS)vs › | $990.12M | -15.09% | 46.85% | 62.20% | 62.20% |
| MeiraGTx Holdings plc (MGTX)vs › | $985.37M | 36.64% | 876.73% | 395.64% | 252.56% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $982.03M | -25.78% | 29.18% | 31.59% | 31.59% |
| Integra LifeSciences Holdings Corporation (IART)vs › | $1.02B | -0.69% | -24.98% | -8.92% | -2.80% |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.02B | -63.62% | -41.08% | -23.78% | -22.76% |
| Lumexa Imaging Holdings, Inc. Common Stock (LMRI)vs › | $1.02B | -4.51% | -33.13% | -42.62% | -42.62% |
| Castle Biosciences, Inc. (CSTL)vs › | $1.04B | -4.13% | -0.56% | -8.16% | -7.12% |
ROE
-11.1%
ROA
-10.2%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -11.06% |
| 2026-03-31 | -12.16% |
| 2025-12-31 | -11.88% |
| 2025-09-30 | -10.43% |
| 2025-06-30 | -10.67% |
| 2025-03-31 | -7.68% |
| 2024-12-31 | -6.75% |
| 2024-09-30 | -9.23% |
| 2024-06-30 | -6.70% |
| 2024-03-31 | -8.48% |
| 2023-12-31 | -16.93% |
| 2023-09-30 | -17.94% |
| 2023-06-30 | -22.62% |
| 2023-03-31 | -21.56% |
| 2022-12-31 | -19.66% |
| 2022-09-30 | -18.22% |
| 2022-06-30 | -15.85% |
| 2022-03-31 | -12.30% |
| 2021-12-31 | -8.92% |
| 2021-09-30 | -5.55% |
| 2021-06-30 | -2.96% |
